2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Highlights on Stage 3 EGFR+ NSCLC: Should Osimertinib Be Considered for Patients With EGFR Exon 21 Mutation in Adjuvant Setting?

225 views
September 28, 2020
Comments 0
Login to view comments. Click here to Login